Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.
Introduction: Bone metastases are the most frequent site of secondary localization of prostate cancer (PCa) and are present in about 90% of cases of advanced disease. Consequently, an adequate management of bone involvement is of pivotal importance in the therapeutic approach and skeletal-related ev...
| Publicado en: | Current Oncology Vol. 29; no. 3; pp. 1709 - 1723 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
MDPI
Mar2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156002878&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 156002878 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Mar2022 vid: 29 iid: 3 pid: 97109 pub: MDPI artinfo: ui: 156002878 156002878 156002878 10.3390/curroncol29030142 156002878 ppf: 1709 ppct: 14 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. aug: au: Mollica, Veronica Nuvola, Giacomo Tassinari, Elisa Nigro, Maria Concetta Marchetti, Andrea Rosellini, Matteo Rizzo, Alessandro Errani, Costantino Massari, Francesco affil: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy sug: subj: Prostatic Neoplasms, Castration-Resistant Therapy Bone Metastases Antibodies, Monoclonal Therapeutic Use Osteonecrosis Zoledronic Acid Therapeutic Use Prostatic Neoplasms, Castration-Resistant Complications ab: Introduction: Bone metastases are the most frequent site of secondary localization of prostate cancer (PCa) and are present in about 90% of cases of advanced disease. Consequently, an adequate management of bone involvement is of pivotal importance in the therapeutic approach and skeletal-related events (SREs) need to be closely monitored and promptly assessed and treated. Bone targeting agents (BTAs), consisting in bisphosphonates and denosumab, are an essential part of the treatment of metastatic prostate cancer that accompanies systemic treatments throughout the most part of the history of the disease. Activity and safety of bone targeting agents: These treatments are correlated to better outcomes in terms of reduction of SREs and, in metastatic castration resistant setting, of increased overall survival (OS), but several important adverse events have to be managed and prevented. Of these, osteonecrosis of the jaw (ONJ) is extremely invalidating and should be managed with a special attention. Discussion: The role of BTAs in prostate cancer is pivotal throughout many stages of the disease, but several toxicities should be quickly recognized and treated. We aim at recollecting evidence on clinical benefit of BTAs, common and specific toxicities, and explore the pathophysiology and clinical aspects of osteonecrosis of the jaw. We present a review of the literature to report the role of the different types of bone targeting agents in the management of prostate cancer with bone metastases with a particular focus on common toxicities and ONJ to recollect current evidences on the activity of these compounds and the correct management of their adverse events. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|